APM
Aptorum Group Ltd - Class A (APM)
Healthcare • NASDAQ • $0.840.00%
- Symbol
- APM
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $0.84
- Daily Change
- 0.00%
- Market Cap
- $6.84M
- Trailing P/E
- N/A
- Forward P/E
- -1.18
- 52W High
- $4.47
- 52W Low
- $0.65
- Analyst Target
- N/A
- Dividend Yield
- N/A
- Beta
- 0.09
Aptorum Group Limited, through its subsidiaries, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in phase 1 clinical trial for the treatment of bacterial infections, such as staphylococcus aureus, mycobacterium tuberculosis, and pseudomonas aeruginosa. The company also develops SACT-COV19, a repurposed small molecule which is in preclinical trial for the treatment of coronavirus disease; SACT-2 and SACT-3; ALS-1, a small molecule which is in preclinical trial to treat bacterial…
Company websiteResearch APM on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.